Linus Health is accelerating its efforts in early brain health detection, applying AI-driven analysis of everyday human behaviours to identify cognitive change earlier and support timely intervention across healthcare and research settings.

The Boston-based digital health company said its platform enables clinicians, health systems, insurers, and life science companies to detect underlying disease processes at a stage when interventions can have the greatest impact. Linus Health highlighted the growing urgency for scalable early detection as the number of Americans living with Alzheimer’s and other dementias is projected to double to nearly 14 million by 2060.

“Brain health is one of the most urgent issues in healthcare and life sciences,” said David Bates, CEO and co-founder of Linus Health. “Across the industry, there is growing recognition that waiting for symptoms to become obvious is no longer acceptable. During 2025, we also saw meaningful expansion in adoption of our platform across health systems, life science companies, and payers, reinforcing that the industry is ready to move from awareness to action around proactive brain health.”

The company has continued to build the scientific evidence base for its approach, publishing peer-reviewed studies demonstrating that its AI-enabled digital cognitive assessments can detect subtle changes associated with Alzheimer’s pathology and cognitive decline earlier than traditional methods. These assessments have been applied across clinical trials, validation studies, and research collaborations, supporting early identification and trial participant stratification.

In 2025, Linus Health also expanded its portfolio with the launch of Anywhere powered by Linus Health™, a remote, clinically validated cognitive assessment platform designed to extend early detection beyond traditional care settings. Additionally, the company advanced its person-centred ePSOM tool, which captures individual goals and daily function primarily in research and life sciences contexts.

Linus Health said its operating model has evolved to focus on distinct business units supporting healthcare delivery, connected care, and life sciences research. Curt Thornton, chief commercial officer, now also serves as president, Connected Care, leading initiatives to build an integrated ecosystem supporting patients from early identification through ongoing care. Leah Ray, chief customer officer, now also serves as president, U.S. Healthcare, overseeing the expansion and operationalisation of the company’s health system footprint.

Showalter added: “Our goal is to scale impact responsibly as the brain health landscape changes. By organising around focused business units, we are better positioned to support clinicians, expand research partnerships, and deliver solutions that address the real constraints health systems face today. This shift positions us to execute with greater clarity and speed, ensuring our teams are aligned to meet rising demand across healthcare delivery, connected care, and life sciences as brain health becomes a clinical priority.”

Linus Health partners with healthcare delivery organisations, research institutions, and life sciences companies to advance proactive intervention and personalised care in brain health, leveraging neuroscience, clinical expertise, and AI to deliver actionable insights and early detection solutions.